X

Trial Profile

Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Satricabtagene autoleucel (Primary)
Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer
Focus Adverse reactions; First in man

Most Recent Events

04 Jun 2019 Results (data cut off: November 30th, 2018; n= 12) assessing safety and efficacy of the autologous CAR-CLDNN18.2 T cells, patients with advanced gastric or pancreatic adenocarcinoma published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
08 Mar 2018 Status changed from not yet recruiting to recruiting.
23 Jul 2017 Planned initiation date changed from 1 May 2017 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com